All In Biotech

Drug Trial Radar · NCT04844866

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT

Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

213

Planned (sponsor's estimate)

Start

Aug 18, 2021

Primary completion

Jan 15, 2025

Study completion Sep 30, 2031

Sponsor

Lead sponsor
Miltenyi Biomedicine GmbHIndustry
Sponsor type
Industry
Collaborators
ICON plc
First posted
Apr 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem cell transplantation. Part II is a Phase II single-arm, open-label, multi-centre study evaluating the efficacy and safety of MB-CART2019.1 in younger, fit participants with R-R DLBCL. Part II will start after completion of enrolment in Part I.

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

  • MB-CART2019.1Genetic

    MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.

  • Standard of CareDrug

    Standard of Care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part I: Event-free survivalTime frame: up to 30 weeks after randomisation
  2. Part II: Best objective response rateTime frame: up to 30 weeks after administration of MB-CART2019.1

Locations

51 sites in 14 countries. Site status is shown where the registry gives one.

  • LKH - Medizinische Universitaet Graz

    Graz, Austria · Active not recruiting

  • Universitatsklinikum Innsbruck Universitatsklinik fur Innere Medizin V

    Innsbruck, Austria · Recruiting

  • Ordensklinikum Linz GmbH Elisabethinen

    Linz, Austria · Recruiting

  • Medizinische Universitaet Wien - Allgemeines Krankenhaus der Stadt Wien (AKH)

    Vienna, Austria · Recruiting

  • Jules Bordet lnstitute

    Anderlecht, Belgium · Recruiting

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

    Leuven, Belgium · Recruiting

  • University Hospital Center Zagreb

    Zagreb, Croatia · Recruiting

  • University Hospital Hradec Kralove

    Hradec Králové, Czechia · Recruiting

  • FNsP Ostrava

    Ostrava, Czechia · Recruiting

  • Helsinki University Comprehensive Cancer Center

    Helsinki, Finland · Not yet recruiting

  • Oulu University Central Hospital

    Oulu, Finland · Recruiting

  • Turku University Hospital

    Turku, Finland · Recruiting

  • Centre Hospitalier Universitaire (CHU) - Hopital Henri Mondor

    Créteil, France · Recruiting

  • CHRU de Lille - Hopital Claude Huriez

    Lille, France · Active not recruiting

  • Centre Hospitalier Lyon Sud, Hospices Civils de Lyon Groupement Hospitalier Sud

    Lyon, France · Active not recruiting

  • Centre Paoli Calmettes

    Marseille, France · Active not recruiting

  • Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hopital Hotel Dieu

    Nantes, France · Active not recruiting

  • Centre Hospitalier Universitaire de Bordeaux - Hopital Haut-Leveque

    Pessac, France · Recruiting

  • Centre Hospitalier Universitaire de Poitiers

    Poitiers, France · Recruiting

  • Institut Universitaire du Cancer Service d´hématologie

    Toulouse, France · Recruiting

  • CHU de Nancy Hopitaux de Brabois

    Vandœuvre-lès-Nancy, France · Recruiting

  • Universitatsklinikum Augsburg

    Augsburg, Germany · Recruiting

  • Universitaetsklinikum Knappschaftskrankenhaus Bochum der Ruhr-Universitat Bochum

    Bochum, Germany · Recruiting

  • Universitaetsklinikum Koeln

    Cologne, Germany · Recruiting

  • Klinikum Erlangen der Friedrich-Alexander-Universitaet Erlangen-Nuernberg

    Erlangen, Germany · Recruiting

  • Universitaetsklinikum Essen

    Essen, Germany · Recruiting

  • University Medical Center Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Universitaetsklinikum Heidelberg

    Heidelberg, Germany · Recruiting

  • Universitätsklinikum Leipzig

    Leipzig, Germany · Recruiting

  • Klinikum der Universitat München, Studienzentrale fur Hematologie der Medizinischen Klinik II

    München, Germany · Recruiting

  • University Hospital Regensburg

    Regensburg, Germany · Recruiting

  • University Hospital of Tuebingen

    Tübingen, Germany · Recruiting

  • Del-Pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet

    Budapest, Hungary · Recruiting

  • Debreceni Egyetem - Orvos es Egeszsegtudomanyi Centrum (DEOEC) (University of Debrecen Medical and Health Science Center)

    Debrecen, Hungary · Recruiting

  • Azienda Ospedaliera San Giovanni Battista Di Torino

    Torino, Italy · Recruiting

  • Amsterdam Universitaire Medische Centra (UMC) - locatie Amsterdam Medisch Centrum (AMC)

    Amsterdam, Netherlands · Recruiting

  • University Medical Center Groningen

    Groningen, Netherlands · Recruiting

  • Leiden University Medical Center (LUMC)

    Leiden, Netherlands · Recruiting

  • Erasmus University Medical Center

    Rotterdam, Netherlands · Active not recruiting

  • Uniwersytecki Szpital Kliniczny - Klinika Hematologii, Terapii Komorkowych i Chorob Wewnetrznych

    Wroclaw, Poland · Active not recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.